Lascco SA
Investing in biomedical discoveries
Lascco SA is a biomedical-technology development private company based in Geneva, Switzerland. The primary objective of Lascco is to bring promising early-stage biomedical technologies – therapeutics and diagnostics – developed in research institutes to the attention of the pharmaceutical industry.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
26.10.2023
Chinese pharma company secures exclusive licence with Abionic and Lascco (startupticker.ch)
18.09.2015
LASCCO annonce un partenariat avec Abionic pour un test de sepsis en 5 minutes (startupticker.ch)
03.11.2014
Swiss start-up and University of Berne develop alternative to antibiotics (startupticker.ch)
28.06.2013
Lascco obtains US patent protecting its biomarker PSP for the diagnosis of sepsis (startupticker.ch)
28.11.2012
Lascco Announces a Licensing Agreement with Abbott (startupticker.ch)
No Jobs
No videos and documents
Innogrants
With the Innogrants, EPFL support financially high-potential projects in which its employees or students are involved.
Lascco SA
Investing in biomedical discoveries
Website:
www.lascco.com
Headquarter:
Genève
Foundation Date:
February 2007
Technology:
- Biotech
Sectors:
- Biotech